Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus SULFISOXAZOLE DIOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus SULFISOXAZOLE DIOLAMINE.
GANTRISIN vs SULFISOXAZOLE DIOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Sulfisoxazole diolamine is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
2-4 g orally initially, followed by 4-8 g/day in 4-6 divided doses for urinary tract infections; 6-8 g/day in 4-6 divided doses for nocardiosis.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
5-10 hours (prolonged in renal impairment; normal half-life in adults ~6 hours)
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: 70-100% (primarily as unchanged drug and acetylated metabolite); Biliary/Fecal: <5%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic